P2X receptor agonist enhances tumor-specific CTL responses through CD70+ DC-mediated Th17 induction

  • Yamamoto, Shinya
  • Matsuo, Kazuhiko
  • Sakai, Sho
  • Mishima, Itsuki
  • Hara, Yuta
  • Oiso, Naoki
  • Kawada, Akira
  • Yoshie, Osamu
  • Nakayama, Takashi

  • Division of Chemotherapy, Kindai University Faculty of Pharmacy, Higashi-osaka, Osaka, Japan

    Department of Dermatology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan

    Emeritus professor, Kindai University, OsakaSayama, Osaka, Japan

    Health and Kampo Institute, Sendai, Miyagi, Japan

Correspondence to: T. Nakayama; E-mail: [email protected]

These authors contributed equally to this study.

Received March 31, 2020

Accepted October 01, 2020

Revised October 31, 2020

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

International Immunology 33(1):p 49-55, January 2021. | DOI: 10.1093/intimm/dxaa068

Corresponding Article

In This Issue

International Immunology 33(1):p 5-6, January 2021. | DOI: 10.1093/intimm/dxaa074
Copyright © The Japanese Society for Immunology 2021. Published by Oxford University Press. All rights reserved.
View full text|Download PDF